肠道代谢物加剧应激性腹泻。

IF 0.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Narumi Ishihara, Shunsuke Kimura, Koji Hase
{"title":"肠道代谢物加剧应激性腹泻。","authors":"Narumi Ishihara, Shunsuke Kimura, Koji Hase","doi":"10.1248/yakushi.24-00190-2","DOIUrl":null,"url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) constitutes a chronic functional gastrointestinal disorder characterized by abdominal pain and irregular bowel habits. Diagnosis typically hinges upon symptomatology, following the exclusion of organic pathologies such as intestinal inflammation and malignancies. IBS manifests with diverse symptoms attributable to aberrant intestinal function, including diarrhea, constipation, and bloating, stratified into four types based on the predominance of diarrhea versus constipation. Radical treatment for IBS remains elusive due to its unknown pathology and etiology, thereby necessitating symptom-focused therapeutic approaches. Certain conditions such as psychiatric disorders, intestinal inflammation, food sensitivities, and Small Intestinal Bacterial Overgrowth (SIBO) exhibit overlaps with or correlations to symptoms of IBS, suggesting that treatment targeting these conditions may ameliorate symptoms of IBS. Emotional stress emerges as a principal risk factor for IBS, precipitating alterations in stress hormone levels and intestinal motility, thereby instigating a spectrum of symptoms associated with the disorder. Additional risk factors for IBS exhibit considerable variability among individuals, encompassing dietary factors that stimulate or influence intestinal function, gluten, the presence of fermentable carbohydrates (fermentable oligosaccharides disaccharides monosaccharides and polyols: FODMAPs), and aspects of the intestinal microbiota and its metabolites. Notably, individuals with IBS demonstrate distinctive alterations in gut microbiota composition compared to healthy controls, indicative of dysbiosis. Furthermore, changes in metabolites such as short-chain fatty acids (SCFAs) in some IBS patients are recognized. In summary, while the precise etiology and underlying pathology of IBS remain elusive, management typically necessitates a multifaceted approach involving lifestyle modifications, targeted symptom therapies, occasional psychological support, and adjunctive measures to regulate the intestinal environment.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 8","pages":"667-672"},"PeriodicalIF":0.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[An Intestinal Metabolite Exacerbates Stress-induced Diarrhea].\",\"authors\":\"Narumi Ishihara, Shunsuke Kimura, Koji Hase\",\"doi\":\"10.1248/yakushi.24-00190-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Irritable bowel syndrome (IBS) constitutes a chronic functional gastrointestinal disorder characterized by abdominal pain and irregular bowel habits. Diagnosis typically hinges upon symptomatology, following the exclusion of organic pathologies such as intestinal inflammation and malignancies. IBS manifests with diverse symptoms attributable to aberrant intestinal function, including diarrhea, constipation, and bloating, stratified into four types based on the predominance of diarrhea versus constipation. Radical treatment for IBS remains elusive due to its unknown pathology and etiology, thereby necessitating symptom-focused therapeutic approaches. Certain conditions such as psychiatric disorders, intestinal inflammation, food sensitivities, and Small Intestinal Bacterial Overgrowth (SIBO) exhibit overlaps with or correlations to symptoms of IBS, suggesting that treatment targeting these conditions may ameliorate symptoms of IBS. Emotional stress emerges as a principal risk factor for IBS, precipitating alterations in stress hormone levels and intestinal motility, thereby instigating a spectrum of symptoms associated with the disorder. Additional risk factors for IBS exhibit considerable variability among individuals, encompassing dietary factors that stimulate or influence intestinal function, gluten, the presence of fermentable carbohydrates (fermentable oligosaccharides disaccharides monosaccharides and polyols: FODMAPs), and aspects of the intestinal microbiota and its metabolites. Notably, individuals with IBS demonstrate distinctive alterations in gut microbiota composition compared to healthy controls, indicative of dysbiosis. Furthermore, changes in metabolites such as short-chain fatty acids (SCFAs) in some IBS patients are recognized. In summary, while the precise etiology and underlying pathology of IBS remain elusive, management typically necessitates a multifaceted approach involving lifestyle modifications, targeted symptom therapies, occasional psychological support, and adjunctive measures to regulate the intestinal environment.</p>\",\"PeriodicalId\":23810,\"journal\":{\"name\":\"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan\",\"volume\":\"145 8\",\"pages\":\"667-672\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1248/yakushi.24-00190-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1248/yakushi.24-00190-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

肠易激综合征(IBS)是一种以腹痛和排便习惯不规则为特征的慢性功能性胃肠道疾病。诊断通常取决于症状,排除器质性病变,如肠道炎症和恶性肿瘤。IBS表现为多种由肠道功能异常引起的症状,包括腹泻、便秘和腹胀,根据腹泻和便秘的优势分为四种类型。由于IBS的病理和病因不明,根治性治疗仍然难以捉摸,因此需要以症状为中心的治疗方法。某些情况,如精神疾病、肠道炎症、食物敏感和小肠细菌过度生长(SIBO)与IBS症状有重叠或相关,表明针对这些情况的治疗可能会改善IBS症状。情绪压力是肠易激综合征的主要危险因素,它会引起应激激素水平和肠道蠕动的改变,从而引发与肠易激综合征相关的一系列症状。肠易激综合征的其他危险因素在个体之间表现出相当大的差异,包括刺激或影响肠道功能的饮食因素、麸质、可发酵碳水化合物(可发酵低聚糖、双糖、单糖和多元醇:FODMAPs)的存在,以及肠道微生物群及其代谢物的各个方面。值得注意的是,与健康对照相比,肠易激综合征患者的肠道微生物群组成发生了明显的变化,表明存在生态失调。此外,一些肠易激综合征患者的代谢物如短链脂肪酸(SCFAs)也发生了变化。总之,虽然IBS的确切病因和潜在病理仍然难以捉摸,但治疗通常需要多方面的方法,包括改变生活方式、靶向症状治疗、偶尔的心理支持和调节肠道环境的辅助措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[An Intestinal Metabolite Exacerbates Stress-induced Diarrhea].

Irritable bowel syndrome (IBS) constitutes a chronic functional gastrointestinal disorder characterized by abdominal pain and irregular bowel habits. Diagnosis typically hinges upon symptomatology, following the exclusion of organic pathologies such as intestinal inflammation and malignancies. IBS manifests with diverse symptoms attributable to aberrant intestinal function, including diarrhea, constipation, and bloating, stratified into four types based on the predominance of diarrhea versus constipation. Radical treatment for IBS remains elusive due to its unknown pathology and etiology, thereby necessitating symptom-focused therapeutic approaches. Certain conditions such as psychiatric disorders, intestinal inflammation, food sensitivities, and Small Intestinal Bacterial Overgrowth (SIBO) exhibit overlaps with or correlations to symptoms of IBS, suggesting that treatment targeting these conditions may ameliorate symptoms of IBS. Emotional stress emerges as a principal risk factor for IBS, precipitating alterations in stress hormone levels and intestinal motility, thereby instigating a spectrum of symptoms associated with the disorder. Additional risk factors for IBS exhibit considerable variability among individuals, encompassing dietary factors that stimulate or influence intestinal function, gluten, the presence of fermentable carbohydrates (fermentable oligosaccharides disaccharides monosaccharides and polyols: FODMAPs), and aspects of the intestinal microbiota and its metabolites. Notably, individuals with IBS demonstrate distinctive alterations in gut microbiota composition compared to healthy controls, indicative of dysbiosis. Furthermore, changes in metabolites such as short-chain fatty acids (SCFAs) in some IBS patients are recognized. In summary, while the precise etiology and underlying pathology of IBS remain elusive, management typically necessitates a multifaceted approach involving lifestyle modifications, targeted symptom therapies, occasional psychological support, and adjunctive measures to regulate the intestinal environment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
169
审稿时长
1 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信